Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;13(7):1603-1610.
doi: 10.1007/s13555-023-00951-x. Epub 2023 Jun 14.

Real-World, Retrospective, Multicenter, Observational Study on the Use of the First Liquid AbobotulinumtoxinA in Italy

Carlo Di Gregorio  1 , Matteo Tretti-Clementoni  2 , Magda Belmontesi  3 , Marina Romagnoli  4 , Alessandro Innocenti  5 , Malvina Zanchi  6 , Lucia Leone  7 , Giovanni Damiani  8   9   10 , Ivano Iozzo  11
Affiliations

Real-World, Retrospective, Multicenter, Observational Study on the Use of the First Liquid AbobotulinumtoxinA in Italy

Carlo Di Gregorio et al. Dermatol Ther (Heidelb). 2023 Jul.

Abstract

Introduction: Randomized controlled trials (RCTs) suggested that liquid formulation of botulinum toxin type A (aboBoNT-A) is safe and effective, but data confirming these characteristics in a real-life heterogenous set of patients are currently lacking. This study aimed to assess the efficacy and safety of the ready-to-use aboBoNT-A solution in adults with moderate-to-severe glabellar wrinkles.

Methods: In this real-life, multicenter, retrospective, observational study, healthy adults were treated at baseline only with aboBoNT-A solution on the glabellar area and followed up for 24 weeks. Re-treatment after 20-24 weeks could also be combined with other aesthetic procedures. Family history of immune-mediated inflammatory diseases (IMIDs) was not an exclusion criterion. Patient-reported outcomes (patient's satisfaction and injection-related pain) and physician-reported outcomes (Physician Global Assessment, PGA) were collected.

Results: Of the 542 patients enrolled in the study, 38 had IMID family history. Injection-related pain was reported in 128 (23.62%) as mild (pain VAS = 1.34 ± 0.87) mainly by non-botulinum toxin treatment-naïve women under 50 years of age. At 48 h, physicians rated the clinical result as "improved" in 64% of patients, conversely 264 patients (48.71%) self-evaluated as "satisfied"/"very satisfied". At 4 weeks a touch-up (< 10 units) was performed in 11 (2.03%) patients and 98.2% were "highly satisfied". Re-treatment was performed in 330 (61.45%) patients, mainly botulinum-experienced, at 20 weeks and in 207 (38.55%), mainly botulinum naïve, at 24 weeks. A total of 403 (74.35%) patients were re-treated with the three-point technique and 201 (37.08%) also received hyaluronic acid filler in the lower central face and middle third. There were no cases of de novo IMIDs.

Conclusions: Real-world data confirmed that aboBoNT-A is a fast, efficient, durable, reproducible, and easy-to-use drug which is also well tolerated in patients with family history of IMID.

Keywords: Botulinum toxin type A; Efficacy; Glabellar wrinkles; Immune-mediated inflammatory diseases (IMIDs); Liquid toxin; Real-life; Safety; Telemedicine.

PubMed Disclaimer

Conflict of interest statement

Carlo Di Gregorio, Matteo Tretti-Clementoni, Magda Belmontesi, Marina Romagnoli, Alessandro Innocenti, Malvina Zanchi, Lucia Leone, Giovanni Damiani, Ivano Iozzo have nothing to disclose.

Figures

Fig. 1
Fig. 1
Histogram comparing glabellar lines severity at T0 and at T2
See this image and copyright information in PMC

References

    1. Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol. 2012;11:42–50. doi: 10.1111/j.1473-2165.2011.00593.x. - DOI - PubMed
    1. Li X, Sui C, Xia X, Chen X. Efficacy and safety of botulinum toxin type A for treatment of glabellar lines: a network meta-analysis of randomized controlled trials. Aesthetic Plast Surg. 2022 doi: 10.1007/s00266-022-03018-y. - DOI - PubMed
    1. Anido J, Arenas D, Arruabarrena C, et al. Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone. Clin Cosmet Investig Dermatol. 2017;10:413–421. doi: 10.2147/CCID.S138274. - DOI - PMC - PubMed
    1. Hilton S, Kestemont P, Sattler G, et al. Liquid abobotulinumtoxinA: pooled data from two double-blind, randomized, placebo-controlled phase III studies of glabellar line treatment. Dermatol Surg. 2022;48(11):1198–1202. doi: 10.1097/DSS.0000000000003594. - DOI - PMC - PubMed
    1. Ascher B, Kestemont P, Boineau D, et al. Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthet Surg J. 2018;38(2):183–191. doi: 10.1093/asj/sjw272. - DOI - PubMed

LinkOut - more resources